Drug Trial Radar · NCT04300556
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
182
Planned (sponsor's estimate)
Start
Aug 6, 2020
Primary completion
Aug 8, 2030
Study completion Aug 8, 2030
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Mar 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer \[OC\], endometrial cancer \[EC\], non-small cell lung carcinoma \[NSCLC\], triple-negative breast cancer \[TNBC\]), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzumab ecteribulin (MORAb-202) in participants with OC and EC at selected doses and to further evaluate the safety and tolerability of farletuzumab ecteribulin (MORAb-202) and (3) dose-optimization part. (divided in two parts: Part A \[OC and EC participants\] and Part B \[OC only\]): Part A: to evaluate other farletuzumab ecteribulin (MORAb-202) treatment regimens for safety, tolerability and preliminary efficacy in participants with OC and EC; to evaluate the addition of short course of oral corticosteroids following every dose of farletuzumab ecteribulin (MORAb-202) administered every 21 days; and to select treatment regimens with farletuzumab ecteribulin (MORAb-202) for further evaluation in Part B. Part B: to evaluate the safety and tolerability of different doses of farletuzumab ecteribulin (MORAb-202) as monotherapy and in combination with lenvatinib and to determine the recommended dose (RD) of farletuzumab ecteribulin (MORAb-202) as monotherapy and in combination with lenvatinib.
Conditions
- Solid Tumor
Interventions
Farletuzumab ecteribulinDrug
Farletuzumab ecteribulin intravenous infusion.
PrednisoneDrug
Prednisone administered orally.
PrednisoloneDrug
Prednisolone administered orally.
DexamethasoneDrug
Dexamethasone administered orally.
LenvatinibDrug
Lenvatinib administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation Part: Recommended Phase 2 Dose (RP2D) of Farletuzumab EcteribulinTime frame: Cycle 1 (Cycle length is equal to [=] 21 days)
- Dose Optimization Part B: Recommended Dose (RD) of Farletuzumab Ecteribulin Monotherapy and in Combination With LenvatinibTime frame: Up to approximately 5 years
- Objective Response Rate (ORR)Time frame: From date of first dose of study drug until first documentation of CR or PR (up to approximately 24 weeks)
- Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Cycle 1 (Cycle length=21 days)
- Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Treatment Discontinuation and Adverse Events of Interest (AEIs)Time frame: Baseline up to 28 days after the last dose of study drug (up to approximately 5 years)
Locations
58 sites in 5 countries. Site status is shown where the registry gives one.
ACRC/Arizona Clinical Research Center, Inc
Tucson, Arizona · Withdrawn
Universty of Arkansas for Medical Sciences
Little Rock, Arkansas · Completed
Stanford Women's Cancer Center
Palo Alto, California · Recruiting
University of Miami
Coral Gables, Florida · Completed
Moffitt Cancer Center and Research Institute
Tampa, Florida · Recruiting
Winship Cancer Institute
Atlanta, Georgia · Completed
Georgia Cancer Center
Augusta, Georgia · Recruiting
Northwestern Memorial Hospital
Chicago, Illinois · Recruiting
Ascension Illinois-Skokie Infustion Center
Skokie, Illinois · Withdrawn
Norton Healthcare
Louisville, Kentucky · Withdrawn
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland · Completed
Karmanos Cancer Institute
Detroit, Michigan · Completed
Henry Ford Hospital
Detroit, Michigan · Withdrawn
MD Anderson Cancer Center at Cooper
Camden, New Jersey · Completed
Columbia University Medical Center
New York, New York · Completed
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
University of Cincinnati Medical Center
Cincinnati, Ohio · Completed
OSU Wxner Medical Center
Hilliard, Ohio · Withdrawn
Oregon Health & Science University
Portland, Oregon · Withdrawn
Medical University of South Carolina
Charleston, South Carolina · Withdrawn
Chattanooga's Program in Women's Oncology
Chattanooga, Tennessee · Completed
Vanderbilt University Medical Center
Nashville, Tennessee · Withdrawn
The University of Texas MD Anderson Cancer Center
Houston, Texas · Withdrawn
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia · Completed
Hôpital de la Croix Saint-Simon
Paris, France · Completed
Hopital Cochin
Paris, France · Completed
Centre Antoine Lacassagne Centre Régional de Lutte Contre Le Cancer
Nice, Alpes-Maritimes, France · Completed
ICANS - Institut de cancérologie Strasbourg Europe
Strasbourg, Bas-Rhin, France · Completed
Institut Paoli Calmettes
Marseille, Bouches-du-Rhone, France · Completed
Hopitaux de La Timone
Marseille, Bouches-du-Rhone, France · Completed
Centre François Baclesse
Caen, Calvados, France · Completed
Clinique Armoricaine de Radiologie-PPDS
Saint-Brieuc, Cote-d'Amore, France · Withdrawn
EDOG Institut de Cancerologie de l'Ouest
Nantes, Loir-Atlantique, France · Completed
Clinique Catherine de Sienne
Nantes, Loir-Atlantique, France · Withdrawn
Centre Oscar Lambret
Lille, Nord, France · Completed
Centre Hospitalier de La Côte Basque
Bayonne, Pyrenees-Atlantiques, France · Completed
Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes
Lyon, Rhone, France · Completed
CLCC-Gustave Roussy Cancer
Vilejuif, Val-de-Marne, France · Completed
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan · Recruiting
Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, Japan · Recruiting
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.